Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709592 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00709592 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 42 participants.
The verdict
NCT00709592, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
Interventions
- RADIATION Total-Body Irradiation
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- BIOLOGICAL Thymoglobulin
- PROCEDURE Allogeneic PBSCT or BMT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-07-21 |
| Est. Completion | 2017-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00709592
The ClinicalTrials.gov registry entry for NCT00709592 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Total-Body Irradiation is the first listed.
NCT00709592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00709592 about?
NCT00709592 is a clinical study titled "Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT". One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
What is the current status of trial NCT00709592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2008-07-21. Estimated completion is 2017-06-28.
What interventions are being tested in trial NCT00709592?
The interventions under investigation include: Total-Body Irradiation (RADIATION), Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Thymoglobulin (BIOLOGICAL), Allogeneic PBSCT or BMT (PROCEDURE).
Who is sponsoring clinical trial NCT00709592?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.